Fig. 8: Src inhibition attenuates bleomycin (BLM)-induced pulmonary fibrosis.
a Schematic representation (biorender.com) of the BLM model and drug administration; n = 5. b Kaplan Meyer survival curve post BLM administration. c Weight change post BLM administration. d Total protein concentration in bronchoalveolar lavage fluids (BALFs), as determined with the Bradford assay. Statistical significance was assessed with two-tailed one-way ANOVA; ****p < 0.0001, ***p = 0.0001. e Inflammatory cell numbers in BALFs, as counted with a hematocytometer. Statistical significance was assessed with two-tailed one-way ANOVA; ****p < 0.0001, *p = 0.0115. f Soluble collagen levels in the BALFs were detected with the direct red assay. Statistical significance was assessed with two-tailed one-way ANOVA; ***p = 0.0004, *p = 0.0473. g Col1a1 mRNA expression was interrogated with Q-RT-PCR. Values were normalized over the expression of the housekeeping gene B2m and presented as fold change over control. Statistical significance was assessed with two-tailed Kruskal Wallis; **p = 0.0094. h Quantification of fibrosis severity in Hematoxylin & Eosin (H/E) stained lung sections via Ashcroft scoring. Statistical significance was assessed with two-tailed one-way ANOVA; ****p < 0.0001, **p = 0.0028/0.0074. i Representative images from lung sections of murine lungs of the indicated genotypes, stained with Fast Green/Sirius Red (F.G/S.R; green/red) and H&E; scale bars = 50 μm. In all panels, all samples are biologically independent; boxplots visualize the median of each distribution; upper/lower hinges represent 1st/3rd quartiles; whiskers extend no further than 1.5 *IQR from the respective hinge. Source data for all panels are provided as a Source Data file.
